BioSpace News Archive

ProLynx, Inc. announced that Richard King, MBA, has been appointed as Chief Executive Officer and as a member of the Board of Directors.

Insulet Corporation announced it has received CE marking under the European Medical Device Regulation for its Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes.

Rocket Pharmaceuticals, Inc. and Renovacor, Inc. announced a definitive agreement under which Rocket will acquire Renovacor in an all-stock transaction for an implied value of approximately $2.60 per share, based on the volume weighted average trading price of Rocket shares of $15.51 for the 30 trading days through and including Monday, September 19, 2022.

BiondVax Pharmaceuticals Ltd. provided encouraging updates related to the strategic research collaboration between BiondVax, the Max Planck Institute for Multidisciplinary Sciences, and the University Medical Center Göttingen towards the development of a pipeline of innovative alpaca–derived nanosized antibody therapies.

NEUWAY Pharma GmbH announced two new appointments in its senior leadership team: Dr Oliver Ernst, formerly NEUWAY’s Chief Operating Officer, was promoted to Chief Executive Officer, and Dr Thomas Christoph was appointed as new Chief Development Officer.

OpGen, Inc. announced the signing of an R&D collaboration agreement with FIND, the global alliance for diagnostics, for the Unyvero A30 RQ platform for use in rapid pathogen ID and AMR testing from blood culture samples in low and middle income countries.

Biomea Fusion, Inc. presented today “Oral menin inhibitor, BMF-219, displays a significant and durable reduction in HbA1c in a type 2 diabetes rat model”, the first of two oral presentations at the EASD Annual Meeting.

Intuity Medical, Inc. announced that the POGO Automatic® Blood Glucose Monitoring System and POGO Automatic® Test Cartridges are now available with discount pricing through the Costco Member Prescription Program.

Invitae and Praxis Precision Medicines , Inc. today announced that real-world clinical insights from Invitae’s Ciitizen platform were utilized as natural history data to support the submission of Praxis’ Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy (DEE).

Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, announced the issuance of U.S. Patent No. 11,446,344.